NCT02857491View on ClinicalTrials.gov

Intravitreal Injection of Ranibizumab Versus Sham Before Vitrectomy in Patients With Proliferative Diabetic Retinopathy

NACompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions
Proliferative Diabetic Retinopathy
Interventions
DRUG

ranibizumab

intravitreal injection of 0.5 mg ranibizumab before vitrectomy

DRUG

sham

sham intravitreal injection before vitrectomy

PROCEDURE

pars plana vitrectomy

surgical procedure to remove the intravitreal hemorrhage and fibrosis membrane, and re-attach the retina, and perform endo laser photocoagulation on retina.

Trial Locations (1)

510060

Zhongshan Ophthalmic Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT02857491 - Intravitreal Injection of Ranibizumab Versus Sham Before Vitrectomy in Patients With Proliferative Diabetic Retinopathy | Biotech Hunter | Biotech Hunter